Company Filing History:
Years Active: 2015-2021
Title: Michael Robert Dermyer: Innovator in Vaccine-Based Immunotherapy
Introduction
Michael Robert Dermyer is a notable inventor based in Carlsbad, CA (US). He has made significant contributions to the field of immunotherapy, particularly in the development of vaccine-based treatments for prostate-associated antigens. With a total of 3 patents to his name, Dermyer's work is paving the way for advancements in cancer treatment.
Latest Patents
Dermyer's latest patents focus on prostate-associated antigens and vaccine-based immunotherapy regimens. The present disclosure provides isolated immunogenic PAA polypeptides, isolated nucleic acid molecules encoding these polypeptides, and vaccine compositions that include either an immunogenic PAA polypeptide or an isolated nucleic acid molecule. Additionally, the patents detail methods relating to the uses of these polypeptides, nucleic acid molecules, and compositions. The innovative vaccine-based immunotherapy regimens involve the co-administration of a vaccine alongside an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.
Career Highlights
Michael Robert Dermyer is currently associated with Pfizer Corporation, a leading pharmaceutical company known for its commitment to research and development in healthcare. His work at Pfizer has allowed him to focus on groundbreaking research that has the potential to change the landscape of cancer treatment.
Collaborations
Dermyer has collaborated with esteemed colleagues such as Joseph John Binder and Helen Kim Cho. These partnerships have fostered an environment of innovation and creativity, contributing to the success of his research endeavors.
Conclusion
Michael Robert Dermyer is a prominent figure in the field of immunotherapy, with a focus on prostate-associated antigens. His innovative patents and collaborations highlight his commitment to advancing cancer treatment through vaccine-based therapies.